In brief
The United Kingdom's government has announced an indefinite ban on the prescription of puberty blockers for adolescents experiencing gender dysphoria. This decision solidifies earlier temporary restrictions imposed this year, impacting individuals under 18 across England, Scotland, Wales, and Northern Ireland. Health Secretary Wes Streeting cited expert opinions warning of substantial safety concerns regarding the administration of these treatments without comprehensive research into their long-term effects.
Mr. Streeting emphasized the need for careful consideration when dealing with this vulnerable demographic and revealed plans for a clinical trial to gather robust evidence on the efficacy and safety of puberty blockers, set to commence next year. This measure follows prior government actions, including an extensive review led by pediatrician Hilary Cass, which concluded that foundational evidence supporting gender medicine practices, like hormone treatments for delaying puberty, was weak. The review's findings led to broader scrutiny of current healthcare protocols regarding young individuals with gender identity issues.
